Editor’s Note March 6, 2012
Spring is on it’s way and things are heating up as well in the healthcare and life science industry. In this week’s Sentinel: Kevin Lupowitz […]
Spring is on it’s way and things are heating up as well in the healthcare and life science industry. In this week’s Sentinel: Kevin Lupowitz […]
AdvaMed 2012, the big medtech conference for industry executives, has launched its website and is calling for proposals for program panels.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This is one of the largest sources of frustration currently among health care companies and investors.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
According to BIO’s statistics, “a majority of investors (56%) still think now is a good time to invest.
Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid.
Spherix has entered into definitive agreements to sell $1.15 million of shares of its common stock and warrants.
Contrast-induced nephropathy (CIN) is a form of acute renal failure precipitated by exposure to these radiocontrast agents. In other words, it is hospital-acquired. The question is: will it kill you?
Copyright © 2024 | WordPress Theme by MH Themes